

Digital Phenotyping: Understanding Human Behavior Through Technology

Letícia Correia*

Department of Botanical Science, Federal University of Pará, Brazil

Editorial

Received: 02-Sep-2025, Manuscript No. jbs-25-171849; **Editor assigned:** 04-Sep-2025, PreQC No. jbs-25-171849 (PQ); **Reviewed:** 13-Sep-2025, QC No. jbs-25-171849; **Revised:** 20-Sep-2025, Manuscript No. JBS-24-171849(R); **Published:** 29-Sep-2025, DOI: 10.4172/2320-0189.14.4.002.

*For Correspondence

Letícia Correia, Department of Botanical Science, Federal University of Pará, Brazil

E-mail: leticia367@gmail.com

Citation: Letícia Correia, Digital Phenotyping: Understanding Human Behavior Through Technology. RRJ Botanical Sci. 2025.14.002.

Copyright: © 2025 Letícia Correia, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Digital phenotyping is the real-time, continuous, and objective measurement of human behavior and physiology through data collected from digital devices, especially smartphones and wearable sensors. The term was first introduced to describe the process of quantifying the human phenotype—the observable characteristics influenced by genetics and environment—using digital technologies. As modern life increasingly revolves around digital interactions, digital phenotyping provides an unprecedented opportunity to understand health, behavior, and disease patterns outside traditional clinical settings.

Discussion

Digital phenotyping harnesses data from sources such as smartphone usage, GPS tracking, typing speed, voice tone, heart rate monitors, and sleep trackers. These data streams offer insights into various aspects of an individual's mental and physical health. For example, changes in communication patterns or mobility may signal the onset of depression or anxiety, while fluctuations in sleep and activity levels may reflect stress or chronic illness.

One of the main advantages of digital phenotyping lies in its ability to collect continuous and passive data. Unlike traditional surveys or clinical visits that rely on self-reporting, digital phenotyping provides objective, high-frequency measurements that can reveal subtle changes over time. This capability makes it particularly valuable in fields such as psychiatry, neurology, and behavioral medicine. Researchers and clinicians can monitor patients remotely, predict relapses, and personalize interventions with greater precision.

However, digital phenotyping also raises important ethical and privacy concerns. The vast amount of personal data collected can expose sensitive information about an individual's habits, emotions, and location. Ensuring informed consent, data anonymization, and secure storage are essential to maintain trust and protect users' rights. Furthermore, while algorithms can detect behavioral patterns, interpreting these signals accurately requires caution, as context and individual variability play crucial roles in human behavior.

Conclusion

Digital phenotyping represents a transformative approach in understanding human health and behavior through technology. By integrating continuous data from digital devices, it enables more personalized, proactive, and precise healthcare. Yet, the field must address ethical, technical, and interpretive challenges to realize its full potential. With responsible use and robust data governance, digital phenotyping could bridge the gap between everyday digital life and modern medicine, ushering in a new era of behavioral and clinical insight.

References

1. Bilen O, Ballantyne CM (2016) Bempedoic Acid (ETC-1002) An Investigational Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep 18: 61.

2. Zagelbaum NK, Yandrapalli S, Nabors C, Frishman WH (2019) Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases. *Cardiol Rev* 27: 49-56.
3. Benoit Viollet, Bruno Guigas, Nieves Sanz Garcia, Jocelyne Leclerc, Marc Foretz, et al. (2012) Cellular and molecular mechanisms of Bempedoic Acid. An overview, *Clinical Science (London)* 122: 253- 270.
4. Phan BA, Dayspring TD, Toth PP (2012) Ezetimibe therapy: mechanism of action and clinical update. *Vasc Health Risk Manag* 8:415-27.
5. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, et al. (2005) A review of its metabolism, pharmacokinetics and drug interactions. *Clin Pharmacokinet* 44: 467-94.